Renalytix launches £10M placing, restructures debt, plans Nasdaq delisting

Renalytix plc

Minimum £10M gross raised at 9p/share; first tranche of £2.1M closes Oct 9, second tranche conditional on shareholder vote.
FY24 preliminary IFRS revenue $2.3M, loss before tax $44.9M (incl. $10.2M impairment), cash $4.7M, net liabilities -$8.5M.
Convertible bond restructured: £2.75M of $11.66M principal converted to shares; balance to new 5.5%/7.5% note due 2029.
Voluntary delisting from Nasdaq effective ~Oct 7; ADSs to trade on OTCQX Marketplace.

item 1.01 item 2.01 item 2.02 item 2.03 item 3.01 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.